Hem › Immunoglobulin light chain-amyloidos › Massachusetts › Boston
Kliniska studier för Immunoglobulin light chain-amyloidos i Boston, MA
7 studier för Immunoglobulin light chain-amyloidos söker deltagare vid platser i och runt Boston (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
RekryterarFas 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Tufts Medical Center, Boston
Teclistamab-Daratumumab in AL Amyloidosis
RekryterarFas 2
- Boston Medical Center, Boston
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
RekryterarFas 1/2
- Research Site, Boston
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
RekryterarFas 3
- Boston Medical Center, Boston
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
RekryterarObservationsstudie
- Boston University Cancer Research Center, Boston
Molecular Imaging of Primary Amyloid Cardiomyopathy
Rekryterar
- Brigham and Womens' Hospital, Boston
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
RekryterarObservationsstudie
- Tufts Medical Center, Boston
Immunoglobulin light chain-amyloidos-studier i andra städer
- Rochester, MN5 studier
- Durham, NC4 studier
- New York City, NY4 studier
- Columbus, OH3 studier
- Cleveland, OH3 studier
Andra studier i Boston
- Bröstcancer112 studier
- Icke-småcellig lungcancer90 studier
- Cancer (alla typer)85 studier
- Metastaserande cancer63 studier
- Kolorektal cancer63 studier
- Lungcancer62 studier
- Äggstockscancer61 studier
- Prostatacancer59 studier
- Depression52 studier
- Endometriecancer50 studier
- Hjärtsvikt44 studier
- Akut myeloid leukemi44 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.